Lupin bags exclusive US rights for diarrhoea drug

Drug indicated for treatment of Diarrhea, was being marketed by US pharmaceutical Romark Laboratories, L C

In an attempt to strengthen its brand revenues in the US, Lupin has acquired US rights to Alinia® for Oral Suspension through its US subsidiary Lupin Pharmaceutical Inc.

The drug is indicated for treatment of diarrhoea and was being marketed by the US pharmaceutical Company Romark Laboratories, L C.

“We are very excited with the addition of Alinia® for Oral Suspension to our Brands portfolio. The agreement demonstrates Lupin’s commitment to grow its brand franchise in the US and bring meaningful products to the paediatric community. Our sales and marketing efforts will commence immediately and we are optimistic that Alinia will contribute to our growth and profitability in the coming quarters and years,” said Vinita Gupta, CEO, Lupin Pharmaceuticals Inc. and Group President, Lupin Limited.

The company already is marketing an antibiotic brand Suprax and Cholesterol control brand Antara in the US that contributed 21% to the company’s US sales during FY13. The company’s US revenues had grown 54% year-on-year to Rs 36,830 crore during FY13.